Transport
Community Howard Regional Health, INC
Community Howard Regional Health, INC was paid $25.53M by Medicaid between Jan 2018 and Dec 2024, across 133 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoCOMMUNITY HOWARD REGIONAL HEALTH, INC
KOKOMO, IN 46902
KOKOMO, IN 46902
33aNPI1902878994assigned 02/03/2006
33bProvider typeLand Ambulance
28Total paid$25.53M
24GClaims338,141
24DCodes billed133
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Land Ambulance providers in Indiana
Rank by total paid#1 of 139
Median peer was paid$304K
This provider vs. median84×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 42,832 | $1.46M | |
| 2019 | 40,690 | $2.84M | |
| 2020 | 35,106 | $2.74M | |
| 2021 | 45,615 | $4.12M | |
| 2022 | 64,431 | $4.77M | |
| 2023 | 59,383 | $5.05M | |
| 2024incomplete | 50,084 | $4.55M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 30,113 | 25,058 | $4.61M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 18% | 37,400 | 26,324 | $4.54M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 22,051 | 19,327 | $3.36M |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 9.8% | 45,976 | 14,696 | $2.51M |
| 41899 | Unlisted procedure, dentoalveolar structures | 4.8% | 713 | 584 | $1.24M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.2% | 19,916 | 12,068 | $1.07M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.8% | 7,849 | 6,785 | $979K |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 2.6% | 5,525 | 4,553 | $662K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.6% | 8,096 | 7,011 | $660K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.1% | 5,680 | 5,152 | $549K |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 2.1% | 4,772 | 4,302 | $546K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.0% | 906 | 388 | $518K |
121 more codes
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | 1.8% | 110 | $470K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | 1.5% | 6,004 | $387K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.5% | 929 | $381K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 2,123 | $336K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 5,183 | $335K |
| Q3014 | Telehealth originating site facility fee | 1.0% | 6,738 | $267K |
| 99285 | Emergency room visit (most serious) | <1% | 1,374 | $178K |
| 93017 | <1% | 1,179 | $173K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 394 | $152K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,442 | $147K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,248 | $138K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 32,368 | $131K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 517 | $96K |
| 90837 | Psychotherapy session, about an hour | <1% | 563 | $82K |
| 59025 | Fetal non-stress test | <1% | 263 | $81K |
| 36415 | Collection of venous blood by venipuncture | <1% | 31,479 | $78K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 615 | $63K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 132 | $56K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 756 | $55K |
| 93458 | <1% | 14 | $53K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,051 | $52K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 282 | $45K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 394 | $45K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 607 | $42K |
| 80053 | Comprehensive metabolic panel | <1% | 8,236 | $38K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 239 | $31K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 468 | $30K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 874 | $29K |
| 71250 | <1% | 209 | $27K | |
| 99221 | <1% | 75 | $24K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,582 | $23K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 63 | $19K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 148 | $17K |
| 80061 | Lipid panel | <1% | 1,817 | $16K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 273 | $10K |
| 84484 | <1% | 1,352 | $10K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 444 | $9K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 13 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,593 | $8K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 563 | $8K |
| 99218 | <1% | 38 | $8K | |
| 99217 | <1% | 37 | $8K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 156 | $8K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 187 | $7K |
| 84480 | <1% | 1,051 | $6K | |
| 80050 | General health panel | <1% | 32 | $5K |
| 80305 | <1% | 594 | $5K | |
| 77336 | <1% | 25 | $5K | |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 161 | $5K |
| 80076 | <1% | 743 | $4K | |
| A0425 | Ground mileage, per statute mile | <1% | 479 | $4K |
| 84439 | <1% | 646 | $4K | |
| 84436 | <1% | 1,134 | $4K | |
| 83690 | <1% | 951 | $4K | |
| 81001 | <1% | 2,005 | $4K | |
| 94060 | <1% | 157 | $4K | |
| 85027 | <1% | 1,134 | $3K | |
| G0378 | Hospital observation service, per hour | <1% | 38 | $3K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 30 | $3K |
| 80081 | <1% | 44 | $3K | |
| 82728 | <1% | 313 | $3K | |
| 81025 | <1% | 454 | $3K | |
| 77300 | <1% | 22 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 416 | $2K |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 35 | $2K |
| 83550 | <1% | 289 | $2K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 839 | $2K |
| 94726 | <1% | 123 | $2K | |
| 87634 | <1% | 30 | $1K | |
| 83540 | <1% | 293 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 123 | $1K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 41 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 29 | $952.74 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 29 | $952.74 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 88 | $914.88 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 41 | $903.57 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 27 | $885.71 |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 34 | $759.88 |
| 82950 | <1% | 173 | $671.49 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 29 | $638.39 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 13 | $513.02 |
| 96376 | <1% | 79 | $442.26 | |
| 80069 | <1% | 197 | $418.58 | |
| 80055 | <1% | 13 | $405.35 | |
| 82947 | <1% | 64 | $324.56 | |
| 87088 | <1% | 77 | $320.29 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 30 | $319.05 |
| 83880 | <1% | 15 | $314.08 | |
| 82607 | <1% | 27 | $214.90 | |
| 82746 | <1% | 27 | $209.54 | |
| 86364 | <1% | 16 | $164.16 | |
| 82784 | <1% | 16 | $132.95 | |
| T2003 | Non-emergency transportation, per trip | <1% | 16 | $126.50 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 401 | $112.81 |
| 82043 | <1% | 28 | $111.77 | |
| 82570 | <1% | 30 | $102.77 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 19 | $102.06 |
| 83735 | <1% | 25 | $87.10 | |
| 82553 | <1% | 42 | $48.78 | |
| 85014 | <1% | 31 | $47.18 | |
| 85018 | <1% | 31 | $46.08 | |
| C1769 | Guide wire | <1% | 31 | $31.20 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 291 | $28.68 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 284 | $26.34 |
| 94729 | 0% | 134 | $0.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 207 | $0.00 |
| 99188 | 0% | 30 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 44 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 13 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 12 | $0.00 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 19 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 257 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 133 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 320 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 114 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 39 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 110 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 24 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 39 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 29 | $0.00 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 33 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTHARP, ELIZABETH (CEO)